Diagnosing the Unknown | GenomeWeb

Diagnosing the Unknown

Premium

As a clinician, Gauri Varadharachary has seen quite a few patients with metastatic tumors for which no amount of tests or imaging could determine the primary tumor site. If after CT scans, PSA testing, mammograms, and more targeted testing, the site still remains elusive, then the patients are diagnosed with carcinoma of unknown primary and are often treated with systemic chemotherapy instead of targeted therapies. Varadharachary, though, is working to change that by developing molecular-based methods to determine the origin of these types of tumors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.